It’s Generics Not PBMs That Keep Pharmaceuticals Affordable
Expenditures on prescription drugs grew 12.4 percent in 2014 and 8.9 percent in 2015. These eye-popping data are not representative of the long-term expenditure trend, however…Read More.
SCPC to Work with Senate to Advance Provision Recognizing Unique Status, Medication Needs of Hospice, Long Term Care (LTC) Patients
Praises U.S. House Support of HR 6, Effort by Rep. Roskam to Assist LTC and Hospice Patients…Read More.
SCPC 2018 Annual Meeting & Business Partners Summit
Monday, July 16 & Tuesday, July 17, 2018 Read More.
CVS-Aetna Back in Spotlight as AT&T-Time Warner Merger Cleared
SCPC Warns Mergers, Concentration Across Related Medicare ‘Part D’ Markets Lessens Competition, Diminishes Patient Choice, Places LTC Pharmacies at Competitive Disadvantage…Read More.
Complete Pricing Transparency Can Help Trump Government Intervention
As the Trump Administration’s plan to lower the cost of prescription drugs continues to develop and unfold, transparency during rebate negotiation is emerging as a top priority…Read More.
Middlemen drive up patient drug costs
Insurers use pharmacy benefits managers to tilt playing field…Read More.
Tackling High Drug Costs: Administration Works to Rein in Middlemen
Few problems generate stronger emotions than the cost of drugs. President Donald Trump identified bringing down drug prices as a key priority in his campaign, and his administration…Read More.
PBMs: Maligned as Middlemen, They’re Hearing Wedding Bells
The industry has been criticized for lack of transparency—and worse. Some see ‘a ton of sense’ in the proposed mergers with insurers and retailers. Others see a risk of even higher drug prices and a need for oversight…Read More.
FDA wants to shorten new drug monopolies to cut costs
In an effort to increase competition and bring down prescription drug prices, FDA Commissioner Dr. Scott Gottlieb wants to speed approval times for rivals to promising new first-to-market medicines…Read More.
Mergers between health insurers and pharmacy benefit managers could be bad for your health
Pharmacy benefit managers, which long ran under the public radar, now have President Trump’s attention. In a recent speech on drug pricing, he called out “the dishonest double-dealing that allows the middleman to pocket rebates and discounts that should be passed on to consumers and patients.”Read More.